Literature DB >> 17122696

Strategies for maximizing clinical effectiveness in the treatment of schizophrenia.

Rajiv Tandon1, Steven D Targum, Henry A Nasrallah, Ruth Ross.   

Abstract

The ultimate clinical objective in the treatment of schizophrenia is to enable affected individuals to lead maximally productive and personally meaningful lives. As with other chronic diseases that lack a definitive cure, the individual's service/recovery plan must include treatment interventions directed towards decreasing manifestations of the illness, rehabilitative services directed towards enhancing adaptive skills, and social support mobilization aimed at optimizing function and quality of life. In this review, we provide a conceptual framework for considering approaches for maximizing the effectiveness of the array of treatments and other services towards promoting recovery of persons with schizophrenia. We discuss pharmacological, psychological, and social strategies that decrease the burden of the disease of schizophrenia on affected individuals and their families while adding the least possible burden of treatment. In view of the multitude of treatments necessary to optimize outcomes for individuals with schizophrenia, effective coordination of these services is essential. In addition to providing best possible clinical assessment and pharmacological treatment, the psychiatrist must function as an effective leader of the treatment team. To do so, however, the psychiatrist must be knowledgeable about the range of available services, must have skills in clinical-administrative leadership, and must accept the responsibility of coordinating the planning and delivery of this multidimensional array of treatments and services. Finally, the effectiveness of providing optimal individualized treatment/rehabilitation is best gauged by measuring progress on multiple effectiveness domains. Approaches for efficient and reliable assessment are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122696     DOI: 10.1097/00131746-200611000-00003

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  17 in total

1.  Antipsychotic treatment of schizophrenia: two steps forward, one step back.

Authors:  Rajiv Tandon
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

2.  Antipsychotic treatment of first-episode or early-onset schizophrenia.

Authors:  Trina Webb; Rajiv Tandon
Journal:  Curr Psychiatry Rep       Date:  2009-08       Impact factor: 5.285

3.  Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.

Authors:  Joseph Parks; Alan Radke; George Parker; May-Ellen Foti; Robert Eilers; Mary Diamond; Dale Svendsen; Rajiv Tandon
Journal:  Schizophr Bull       Date:  2008-04-02       Impact factor: 9.306

4.  Health insurance coverage among persons with schizophrenia in the United States.

Authors:  Elizabeth Khaykin; William W Eaton; Daniel E Ford; Christopher B Anthony; Gail L Daumit
Journal:  Psychiatr Serv       Date:  2010-08       Impact factor: 3.084

5.  Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.

Authors:  Pudtan Phanthunane; Theo Vos; Harvey Whiteford; Melanie Bertram
Journal:  Cost Eff Resour Alloc       Date:  2011-05-13

6.  Is seroquel developing an illicit reputation for misuse/abuse?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2010-01

Review 7.  Histamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective.

Authors:  Danish Mahmood
Journal:  Int J Health Sci (Qassim)       Date:  2016-10

8.  A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.

Authors:  Shi-Fu Xiao; Hai-Bo Xue; Xia Li; Chao Chen; Guan-Jun Li; Cheng-Mei Yuan; Ming-Yuan Zhang
Journal:  Neurosci Bull       Date:  2011-08       Impact factor: 5.203

Review 9.  Reducing variation in the pharmacologic treatment of schizophrenia: defining acceptable standards of treatment.

Authors:  Robert J Constantine
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

10.  Bipolar and Depressive Disorders in Diagnostic and Statistical Manual of Mental Disorders-5: Clinical Implications of Revisions from Diagnostic and Statistical Manual of Mental Disorders-IV.

Authors:  Rajiv Tandon
Journal:  Indian J Psychol Med       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.